many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K
真核延伸因子2激酶(eEF2K)是一种Ca2 + /
钙调蛋白依赖性蛋白激酶,属于非典型Ser / Thr蛋白激酶的小家族。最近有报道称eEF2K在许多类型的癌症中被高度激活或过表达。因此,eEF2K被认为是有希望的治疗靶标。在这项研究中,我们通过虚拟高通量筛选发现了β-苯丙
氨酸支架,并设计和合成了46种衍
生物,评估了其对eEF2K的抑制活性和细胞毒性。经过几轮激酶和抗增殖活性筛选后,我们发现了具有最佳eEF2K酶促活性(IC50为5.5μM)和抗增殖活性(
MDA-MB-231细胞,IC50为12.6μM,
MDA)的eEF2K
抑制剂(21l) -MB-436细胞,IC50为19.8μM。而且,我们发现21l可以通过
MDA-MB-231和
MDA-MB-436细胞的凋亡途径诱导
细胞死亡。随后,我们评估了其在体内的抗肿瘤活性和诱导细胞凋亡的机制。这些结果表明21l通过在乳腺癌的异种移植小鼠模型(M